Treatment of Gram-Negative Septic Toxic Diseases with an Immunoglobulin Preparation Containing IgG, IgM and IgA: A Prospective Randomized Clinical Trial

Schedel, I.; Dreikhausen, Ursula; Nentwig, B.; Höckenschneider, M.; Rauthmann, D.; Balikcioglu, S.; Coldewey, R.; Deicher, H.

doi:10.1007/978-3-642-77405-8_154

Cited by 1 publication

(1 citation statement)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Alejandra et al (8) have performed a meta-analysis based on five trials (24,28,(30)(31)(32). These authors calculated an overall dramatic reduction in mortality among adult patients treated with IVIG compared with control patients (n=222, RR=0.60, 95% CI 0.47 to 0.77) (8).…”

Section: Polyclonal Intravenous Immunoglobulinmentioning

confidence: 99%

Polyclonal Intravenous Immunoglobulin for the Prophylaxis and Treatment of Infection in Critically Ill Adults

Laupland

2002

Canadian Journal of Infectious Diseases

View full text Add to dashboard Cite

KB Laupland. Polyclonal intravenous immunoglobulin for the prophylaxis and treatment of infection in critically illInfection is a major cause of morbidity and mortality in critically ill patients. Despite advances in technology, its mortality rate has changed minimally over the past two decades, and new therapies are needed. Polyclonal intravenous immunoglobulin (IVIG) has been investigated both as a preventive and a treatment modality for sepsis and septic shock in critically ill adult patients. Prophylaxis with IVIG has been shown to reduce significantly the incidence of infection, particularly pneumonia, in selected postsurgical intensive care patients. However, it does not reduce mortality. The risk-benefit and cost effectiveness of this therapeutic intervention have not been determined, and its routine use is therefore not recommended. Treatment with IVIG has been shown in a number of small trials and a meta-analysis to reduce dramatically sepsis and septic shock mortality. However, a large, unpublished randomized trial has apparently shown no mortality benefit with this therapy. Despite limited evidence, IVIG has become the standard of care for the management of group A streptococcal toxic shock syndrome. At present, clinical equipoise exists for the use of IVIG in the treatment of sepsis and septic shock, and further study is needed.

show abstract

Section: Polyclonal Intravenous Immunoglobulinmentioning

confidence: 99%

Polyclonal Intravenous Immunoglobulin for the Prophylaxis and Treatment of Infection in Critically Ill Adults

Laupland

2002

Canadian Journal of Infectious Diseases

View full text Add to dashboard Cite

show abstract

Treatment of Gram-Negative Septic Toxic Diseases with an Immunoglobulin Preparation Containing IgG, IgM and IgA: A Prospective Randomized Clinical Trial

Cited by 1 publication

References 21 publications

Polyclonal Intravenous Immunoglobulin for the Prophylaxis and Treatment of Infection in Critically Ill Adults

Polyclonal Intravenous Immunoglobulin for the Prophylaxis and Treatment of Infection in Critically Ill Adults

Contact Info

Product

Resources

About